Currently, most tumor immune therapy strategies, such as chimeric antigen receptor T cell therapy (CAR-T), were mainly based on αβ T cells (CD4, CD8 T) and had been applied in treating refractory pre-B cell acute lymphoblastic leukemia and diffuse large B cell lymphoma (34, 35). This evidence concerns the gene CD8A and neoplasm.